The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.
Read More…
Industry, Sector and Symbol
Industry Patent owners & lessors
Sub-IndustryN/A
SectorMedical
Phone480-245-5960
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$31.79 million
Profitability
Miscellaneous
Employees138
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable
Joint (NASDAQ:JYNT) Frequently Asked Questions
What is Joint's stock symbol?
Joint trades on the NASDAQ under the ticker symbol "JYNT."
How were Joint's earnings last quarter?
Joint Corp (NASDAQ:JYNT) issued its quarterly earnings results on Thursday, May, 9th. The company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.06. The business earned $10.68 million during the quarter, compared to analysts' expectations of $8.90 million. Joint had a return on equity of 109.02% and a net margin of 4.50%. View Joint's Earnings History.
When is Joint's next earnings date?
What price target have analysts set for JYNT?
4 brokerages have issued twelve-month price targets for Joint's stock. Their forecasts range from $18.00 to $23.00. On average, they anticipate Joint's stock price to reach $20.50 in the next twelve months. This suggests a possible upside of 28.6% from the stock's current price. View Analyst Price Targets for Joint.
What is the consensus analysts' recommendation for Joint?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Joint in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Joint.
What are Wall Street analysts saying about Joint stock?
Here are some recent quotes from research analysts about Joint stock:
- 1. According to Zacks Investment Research, "The Joint Corp. is a healthcare franchisor of chiropractic clinics. The Company's plans include: Single Visit, Premium Wellness Plan and Wellness Plan. It also provides a family wellness plan. The Company also provides removal of subluxations. It operates its clinics across: Albany, New York; Austin, Texas; Brentwood, California; Fort Mill, South Carolina; Lubbock, Texas; Lynnwood, Washington; Middletown, New Jersey; San Antonio, Texas; San Diego, California and Spartanburg, South Carolina, among others. The Joint Corp. is headquartered in Scottsdale, Arizona. " (6/5/2019)
- 2. Maxim Group analysts commented, "Yesterday after the market close, JYNT reported 4Q18 results that beat estimates across the board and issued better-than-expected 2019 financial guidance. The company opened 22 franchise clinics in 4Q18, versus our estimate of 15, and closed two, for a total of 394. Its corporate clinic count remained at 48. We raise our 2019 and 2020 revenue estimates, as well as out-year top- and bottom-line numbers, as we expect a significantly higher rate of franchise and corporate clinic openings going forward. As a result, we increase our price target to $18, from $11." (3/8/2019)
Has Joint been receiving favorable news coverage?
Headlines about JYNT stock have been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Joint earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Joint.
Who are some of Joint's key competitors?
Some companies that are related to Joint include TiVo (TIVO), Digital Turbine (APPS), Acacia Research (ACTG), Liberty Tax (TAXA), Quarterhill (QTRH), Research Frontiers (REFR), Finjan (FNJN), XCel Brands (XELB), Marathon Patent Group (MARA), MGT Capital Investments (MGTI), ARC Group (ARCK), Spherix (SPEX), XpresSpa Group (XSPA), Patriot Scientific (PTSC) and American Restaurant Partners LP Class A Partnership Units (ICTPU).
What other stocks do shareholders of Joint own?
Who are Joint's key executives?
Joint's management team includes the folowing people:
- Mr. Peter D. Holt, CEO, Pres & Director (Age 60)
- Jake Singleton, Chief Financial Officer (Age 37)
- Mr. Jorge Armenteros, VP of Operations
- Dr. James Edwards, Chief Chiropractic & Compliance Officer
- Mr. Craig P. Colmar, Sec. (Age 66)
When did Joint IPO?
(JYNT) raised $20 million in an IPO on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company served as the underwriters for the IPO and Sanders Morris Harris was co-manager.
Who are Joint's major shareholders?
Joint's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sanders Morris Harris LLC (4.70%), Skylands Capital LLC (3.84%), HighTower Advisors LLC (2.62%), Acadian Asset Management LLC (1.58%), Goldman Sachs Group Inc. (1.12%) and Granite Investment Partners LLC (1.08%). Company insiders that own Joint stock include James H Amos Jr, John P Meloun, Peter D Holt and Ronald V Davella. View Institutional Ownership Trends for Joint.
Which major investors are selling Joint stock?
JYNT stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Skylands Capital LLC, HighTower Advisors LLC, Greenwood Capital Associates LLC, Punch & Associates Investment Management Inc., Perkins Capital Management Inc. and Renaissance Technologies LLC. Company insiders that have sold Joint company stock in the last year include John P Meloun and Ronald V Davella. View Insider Buying and Selling for Joint.
Which major investors are buying Joint stock?
JYNT stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Granite Investment Partners LLC, BlackRock Inc., Acadian Asset Management LLC, Tibra Equities Europe Ltd, Spark Investment Management LLC, O Shaughnessy Asset Management LLC and Dimensional Fund Advisors LP. Company insiders that have bought Joint stock in the last two years include James H Amos Jr, John P Meloun and Peter D Holt. View Insider Buying and Selling for Joint.
How do I buy shares of Joint?
Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Joint's stock price today?
One share of JYNT stock can currently be purchased for approximately $15.94.
How big of a company is Joint?
Joint has a market capitalization of $219.65 million and generates $31.79 million in revenue each year. The company earns $250,000.00 in net income (profit) each year or $0.04 on an earnings per share basis. Joint employs 138 workers across the globe.View Additional Information About Joint.
What is Joint's official website?
How can I contact Joint?
Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at 480-245-5960 or via email at [email protected]
MarketBeat Community Rating for Joint (NASDAQ JYNT)
MarketBeat's community ratings are surveys of what our community members think about Joint and other stocks. Vote "Outperform" if you believe JYNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JYNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
